Abstract. In order to further elucidate the potential correlations and treatments of IgA nephropathy (IgAN) and hypertensive nephropathy (HT), bioinformatics analysis of IgAN and HT was performed. The mRNA expression profiles of human renal biopsy samples from patients with IgAN, patients with HT and pre-transplant healthy living controls (LD) were downloaded from the Gene Expression Omnibus database. Then, the differentially expressed genes (DEGs) were identified and functions of DEGs were analyzed. Finally, the regulatory networks containing DEGs and related-transcription factors (TFs) were constructed using Cytoscape software. When compared with the LD group, 134 and 188 DEGs were obtained in the IgAN and HT groups, respectively. A total of 39 genes were altered in the HT group when compared with the IgAN group. In addition, 66 genes were shared in the IgAN and HT groups when compared with the LD group, 6 of which [early growth response 1, activating transcription factor 3, nuclear receptor subfamily 4 group A member 2 (NR4A2), NR4A1, v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog F and Kruppel like factor 6] were identified as TFs. In addition, DEGs including interleukin (IL) 1 receptor antagonist, collagen type 4 α2 chain, IL8, FBJ murine osteosarcoma viral oncogene homolog and somatostatin were enriched in a number of inflammation-associated biological processes, and DEGs including structural maintenance of chromosomes protein 3, v-crk avian sarcoma virus CT10 oncogene homolog and myosin 6 were enriched in non-inflammation-associated biological processes. Therefore, the differentially expressed TF genes and the genes associated with inflammation may be effective as potential therapeutic targets for IgAN and HT.
Introduction
Chronic kidney disease has become a critical public health concern in China (1). IgA nephropathy (IgAN), the most prevalent type of glomerulonephritis in humans, is characterized by the expansion of the glomerular mesangial matrix with mesangial cell proliferation and/or mononuclear cell infiltration (2, 3) . This disease has a variable course and can lead to renal failure (4) . Hypertensive nephropathy (HT) is a medical condition referring to damage to the kidney due to chronic high blood pressure. IgAN and HT affect a large proportion of the population and induce high levels of pain in patients worldwide (5) . Thus, improving strategies for early diagnosis and screening of disease biomarkers in IgAN and HT are key issues.
Previously, a number of biomarkers have been identified for the detection kidney damage at earlier stages of progression, such as proteinuria and serum creatinine. Urinary IgA and IgG concentrations have been revealed to be higher in patients with IgAN than in healthy controls and in patients with other renal diseases (6) . Urinary excretion of interleukin 6 (IL6) has been reported to predict long-term renal outcomes in patients with IgAN (7) . In addition, serum galactose-deficient IgA1 and glycan-specific autoantibody levels have been identified as potential candidates for diagnostic biomarkers of IgAN (8) . Furthermore, the urinary expressions of transforming growth factor-β, monocyte chemoattractant protein-1 and collagen IV are associated with HT (9) . However, the underlying association between these factors and a variety of chronic kidney diseases remains largely unknown and there is still a lack of effective treatments for IgAN and HT.
In the present study, in order to gain a deeper insight into the potential correlations and treatments of IgAN and HT, the mRNA expression profiles of three types of human renal biopsy samples from patients with IgAN and HT, and pre-transplant healthy living controls (LD) were analyzed to obtain a set of differentially expressed genes (DEGs) and transcription factors (TFs). Finally, functional enrichment was performed to analyze the potential functions of DEGs and to identify candidate biomarkers and treatment targets.
Materials and methods
Microarray data and data preprocessing. mRNA expression profiles (GSE37460) (10) were extracted from the Gene
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Expression Omnibus database (http://www.ncbi.nlm.nih .gov/geo/) (11) . The total microarray contained 69 chips of human renal biopsy samples from 27 patients with IgAN, 15 patients with HT and 27 LD controls (total n=69). Renal biopsies were obtained following the collection of informed written consent from all patients and approval from the ethics committee of European Renal cDNA Bank-Kröner-Fresenius biopsy bank (ERCB-KFB) and the specialized subcommittee for internal medicine of the cantonal ethics committee of Zurich (10) . RNA from the glomeruli and tubulointerstitial compartments was obtained and processed for hybridization on Affymetrix microarrays, as previously described (10) . The expression profiles of 22,283 probe sets from 51 samples (27 IgAN, 15 HT and 9 LD samples) were analyzed by GPL14663 Affymetrix Genechip Human Genome HG-U133A (Affymetrix, Inc., Santa Clara, CA, USA) and 54,675 probe sets from 18 LD samples were analyzed by GPL11670 Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Inc.). To ensure the consistency of the data source and platform, the results from these 51 samples were selected for further analysis. The probe-level data in CEL files were converted into the mRNA expression profiles. Raw data from the 51 samples were preprocessed using the Guanine Cytosine Robust Multi-Array Analysis method (12) with the Affy package (13, 14) in R. The Affmetrix Microarray Suited 5 calls (MAS5calls) algorithm was used for Affymetrix CEL file analysis. Then, the probe-level data in CEL files were converted into the mRNA expression profiles. Functional annotation of DEGs. Genomatix was used to identify the enriched functions and pathways in DEGs. The results demonstrated that the 66 shared DEGs in IgAN vs. LD and HT vs. LD were enriched in 245 Gene Ontology (GO) terms (including vasculature development, circulatory system development and cardiovascular system development) and significantly enriched in 3 pathways, including hemoglobin's chaperone (P=1.80e-4; Fig. 4A ), signal dependent regulation of myogenesis by corepressor microtubule interacting and transport (P=2.74e-3; Fig. 4B ), and nuclear factor of activated T cells and hypertrophy of the heart (P=7.35e-3; Fig. 4C ). In addition, 24 of the 66 shared DEGs were revealed to be associated with kidney cancer, including inhibitor of DNA binding 1 dominant negative helix-loop-helix protein, early growth response 1 (EGR1) and integrin α8 (Table I) .
Screening of
The screened 39 DEGs in the HT vs. IgAN group were divided into three classes: Class I, 10 shared genes in HT vs. IgAN and IgAN vs. LD; class II, 16 shared genes in HT vs. IgAN and HT vs. LD; class III, 13 specific genes HT vs. IgAN (Table II) . GO enrichment indicated that IL1 receptor antagonist (IL1RN) and collagen type IV α2 (COL4A2) in class I were enriched in inflammation-associated biological processes such as negative regulation of the IL1-mediated signaling pathway and negative regulation of heterotypic cell-cell adhesion. Structural maintenance of chromosomes 3 (SMC3), v-crk avian sarcoma virus CT10 oncogene homolog (CRK), caldesmon 1 (CALD), myosin VI (MYO6), type I DNA topoisomerase (TOP1), ST3 β-galactoside α-2,3-sialyltransferase 1 (ST3GAL1), peptidylprolyl isomerase G (PPIG), kin Of IRRE like (Drosophila; KIRREL), ankyrin repeat domain 12 (ANKRD12) and tetratricopeptide repeat domain 3 (TTC3) in class II were enriched in noninflammation-associated biological processes including genetic transfer, DNA mediated transformation and actin filament-based process. 
Discussion
Currently, bioinformatics analysis provides a high-efficiency method to study renal disease. In the present study, in order to extend our understanding of IgAN and HT, 39 DEGs in patients with HT were compared with those in patients with IgAN and 66 shared DEGs in IgAN vs. LD and HT vs. LD were identified; their associated TFs were screened as well. These genes may provide a basis for the identification of potential biomarkers. In addition, 6 DEGs were identified as TFs and they may be effective as potential therapeutic targets.
The results demonstrated that 66 genes were significantly altered in patients with IgAN and HT when compared with healthy controls, among which EGR1, ATF3, NR4A2, NR4A1, MAFF and KLF6 were identified as TFs. EGR1, a member of the early growth response family of zinc finger TFs, modulates the regulation of cluster of differentiation 40 ligand (CD40L) expression in megakaryocytes (18) . CD40L is important in the development of cardiovascular disease and a number of chronic autoimmune inflammatory diseases that target the vasculature such as chronic kidney disease (19) . ATF3, a member of the ATF/CREB family 
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of TFs, regulates transcription by binding to DNA sites as a homodimer or heterodimer with c-JUN proteins (20) . In addition, EGFR1 and ATF3 have been reported to regulate the expression of inflammation-and immune-associated genes (21) . NR4A2 and NR4A1, members of the nuclear hormone receptor subfamily, are involved in cell apoptosis and carcinogenesis (22) . MAFF has been associated with the cellular stress response and detected in the kidney (23) . KLF6, a DNA-binding protein containing a triple zinc-finger motif, serves a role during kidney development and, more specifically, during the development of the renal collecting duct system (10) . Therefore, the results of the present study suggested that EGR1, ATF3, NR4A2, NR4A1, MAFF and KLF6, serve as TFs and serve important roles during the development of human kidney. Thus, they could be used as candidate therapeutic targets for IgAN and HT. In addition, 39 genes were screened in HT samples and compared with IgAN samples; these genes were then divided into three classes. IL1RN and COL4A2 belong to class I, which were altered in IgAN vs. LD group. IL1RN is involved in autoinflammatory disease (24) and may contribute to the risk of IgAN (25, 26) . COL4A2 is a member of the collagen type IV family that may be effective as a marker of renal dysfunction (27) . Furthermore, IL1RN and COL4A2 were enriched in a number of inflammation-associated biological processes such as the negative regulation of the IL1-mediated signaling pathway and negative regulation of heterotypic cell-cell adhesion. Genes in class II were also altered in HT vs. LD, including SMC3, CRK, CALD, MYO6, TOP1, ST3GAL1, PPIG, KIRREL, ANKRD12 and TTC3. The results indicated that SMC3 was modulated by CREB5, a TF belonging to the CREB protein family. SMC3 is also involved in sister chromatid cohesion (28) . The GO enrichment results demonstrated that genes including SMC3, CRK and MYO6 were enriched in non-inflammation-associated biological processes (including genetic transfer, DNA mediated transformation and actin filament-based process). Thus, the authors speculated that the genes in class II may particulate in the cell cycle of HT cells. In addition, IL8, FOS, PPBP, SST, DIS3, KIF3B, RBM25, ARHGAP28 and EPB41L5 in class III were specific DEGs in HT vs. IgAN. IL8, a novel leukocyte chemotactic activating cytokine, has been observed to serve a causative role in acute inflammation by activating neutrophils (29) . The expression of SST in IgAN increased and thus may be involved in the pathogenesis of inflammatory renal disease (30) . FOS is thought to be involved in the treatment of diabetic nephropathy (31) , which is closely associated with HT. Therefore, the results of the present study also suggested that IL1RN and COL4A2 may be effective biomarkers in patients with IgAN, genes in class II (including SMC3, CRK and CALD) may serve as biomarkers for patients with HT and genes in class III (including IL8, FOS and SST) may be alternative biomarkers for IgAN and HT.
In conclusion, the present study screened a large number of DEGs and their TFs in IgAN and HT samples, which were then compared with healthy controls by analyzing mRNA expression profiles. The results suggested that EGR1, ATF3, NR4A2, NR4A1, MAFF and KLF6 may be candidate targets for the treatment of IgAN and/or HT. In addition, genes that were screened in HT samples and compared with IgAN samples, including IL1RN, COL4A2, SMC3, CRK and MYO6, IL8, FOS and SST, may be useful as biomarkers for IgAN and/or HT. However, the majority of candidate biomarkers are still being validated. Therefore, further investigation is required into the role of these biomarkers and targets in appropriate, larger and randomized cohorts, prior to their use in routine clinical screening.
